Niacin treatment increases plasma homocyst(e)ine levels

American Heart Journal

Volumn 138, Issue 6 I, 1999, Pages 1082-1087

  Garg, R ^a   Malinow, M R ^a   Pettinger, M ^a   Upson, B ^a   Hunninghake, D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; FOLIC ACID; HOMOCYSTEINE; LIPOPROTEIN; NICOTINIC ACID;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTERY DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0032737365     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70073-6     Document Type: Article

References (30)

1. Genestt JJ, McNamara JR, Salem DN, Wilson PNF, Schaefer EJ, Malinow MR. Plasma homocysteine levels in men with premature coronary disease. J Am Coll Cardiol 1990;16:1114-9.
2. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
3. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker; 1992. p. 183-236.
4. Stampfer MJ, Malinow MR, Willet WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyste(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-81.
5. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994;236:603-17.
6. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995;332:286-91.
7. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
8. Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991;13:128-36.
9. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-13.
10. Brattstrom L, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid: an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
11. Ubbink JB, Vermank WJH, Van der Merwe A, Becker PJ, Delport R, Potgreter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927-33.
12. Refsum H, Ueland PM, Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986;46:5385-91.
13. Broxson EH, Stork LC, Allen RH, Stabler SP, Kolhouse JF. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989;49:5858-62.
14. Ermens AA, Refsum H, Rupreht J, Spijkers LJ, Guttormsen AB, Lindemans J, et al. Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination of homocysteine and folate in plasma urine. Clin Pharmacol Ther 1991;49:385-93.
15. Kang SS, Wong PWK, Curley K. The effect of D-penicillamine on protein-bound homocyst(e)ine in homocystinurics. Pediatr Res 1982; 16:370-2.
16. Kang SS, Wong PWK, Glickman PB, MacLeod CM, Jaffe LA. Protein-bound homocyst(e)ine in patients with rheumatoid arthritis undergoing D-penicillamine treatment. J Clin Pharmacol 1986; 26:712-5.
17. Blankenhorn DH, Malinow MR, Mack WJ. Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Art Dis 1991;2:357-60.
18. Willet WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
19. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willet WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
20. Smolin LA, Schneider JA. Measurement of total plasma cysteamine using high performance liquid chromatography with electrochemical detection. Anal Biaochem 1988;168:374-9.
21. Malinow MR, Kang SS, Taylor IM, Wong PWK, Coull B, Inahara T, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-8.
22. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Art Dis 1990;1:215-20.
23. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982;38:963-74.
24. Brattstrom L, Israelsson B, Norrving B, Berggvist D, Thorne J, Hultberg B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis 1990;81:61-0.
25. Molgaard J, Malinow MR, Lassvik C, Holm A-C, Upson B, Olsson AG. Hyperhomocyst(e)inaemia. J Intern Med 1992;231:273-9.
26. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
27. Jencks DA, Matthews RG. Allosteric inhibiton of methylenetetrahydrofolate reductase by adenosylmethionine. J Biol Chem 1987;262:2485-93.
28. Kutzbach C. Stokstad ELR. Mammalian methylenetetrahydrofolate reductase: partial purification, properties, and inhibition by S-adenosylmethionine. Biochem Biophys Acta 971;250:459-77.
29. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992;55:131-8.
30. Basu TK, Mann S. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmocological levels of niacin without reducing niacin's hypolipidemic effects. J Nutr 1997;127:117-21.